Q-omics provides the consensus-scored LYPD2 profile across patient tissues and cancer cell-line models. LYPD2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LYPD2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, LYPD2 RNA expression shows 8,850 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, HNSC, and TGCT as cancer lineages where LYPD2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LYPD2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LYPD2 survival associations across molecular data types. LYPD2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LYPD2 RNA expression–survival associations across cancer types. High LYPD2 expression shows unfavorable associations in BRCA, UVM and LUAD, but favorable associations in KIRC, CESC and LIHC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LYPD2 RNA expression.
This table summarizes LYPD2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LYPD2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LYPD2 shows lower tumor expression in HNSC, LUAD, LIHC, KIRP and CHOL and higher tumor expression in KIRC. The HNSC box plot shows higher LYPD2 RNA expression in normal versus tumor tissue (log2 FC = −3.068, t-test p < 0.001).
This table shows molecular features associated with LYPD2 in patient tissues and cancer cell lines. In patient samples, LYPD2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, LYPD2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
